Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: A meta-analysis

Clinical Infectious Diseases

Volumn 40, Issue 5, 2005, Pages 670-676

  Ena, Javier ^a,c   Valls, Victoria ^b  

^a Marina Baixa Hospital   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^c HOSPITAL MARINA BAIXA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; PYRIDOXINE DERIVATIVE; RIFAMPICIN; TUBERCULIN;

BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LIVER TOXICITY; META ANALYSIS; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; ISONIAZID; RIFAMPIN; TUBERCULOSIS;

EID: 15044361765     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/427802     Document Type: Review

References (19)

1. American Thoracic Society and Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infections. Am J Respir Crit Care Med 2000; 161:S221-47.
2. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970; 26:28-106.
3. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:289-91.
4. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations-United States 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733-5.
5. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax 1998; 53:536-48.
6. Jadad AR, Moore RA, Caroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12.
7. Cohen J. Weighted kappa: nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70:213-20.
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-88.
9. The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use: points to consider on the choice of non-inferiority margin. http://www.emea.eu.int/pdfs/human/ewp/215899en.pdf. Accessed 4 June 2004.
10. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
11. Sterne JAC, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323:101-5.
12. Hong Kong Chest Service/Tuberculosis Research Centre, Madras/British Medical Research Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophytaxis regimens in patients with silicosis in Hong Kong. Am Rev Respir Dis 1992; 145:36-41.
13. Martinez-Alfaro E, Solera J, Serna E, et al. Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis [in Spanish]. Med Clin (Barc) 1988; 111:401-4.
14. Martinez-Alfaro E, Cuadra F, Solera J, et al. Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus [in Spanish]. The GECMEI Group. Med Clin (Barc) 2000; 115:161-5.
15. Rivero A, López-Cortés L, Castillo R, et al. Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy [in Spanish]. Enferm Infecc Microbiol Clin 2003; 21:287-92.
16. Whalen CC, Johnson JL, Okwera A, et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. N Engl J Med 1997; 337:801-8.
17. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; 2:CD001363.
18. Bucher HC, Griffith LE, Guyatt GH, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13:501-7.
19. Schultz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology. JAMA 1994; 272:125-8.